An active phase I study was designed to evaluate the safety and tolerance of tremelimumab, anti‐CTLA‐4 antibody and durvalumab in various advanced solid tumours including cervical cancer (NCT01975831). This evidence concerns the gene CTLA4 and cervical cancer.